ArticleFrontiers in veterinary science2026
Adipose-derived mesenchymal stem cell exosomes ameliorate copper metabolism dysregulation and reduce cuproptosis caused by liver IRI.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatic ischemia reperfusion injury is an important pathological factor leading to complications after hepatectomy and transplantation. Although cuproptosis has been reported as a new paradigm of programmed death triggered by copper homeostasis imbalance, its regulatory mechanisms and intervention strategies in liver IRI remain to be fully elucidated. The purpose of this study was to reveal the role of cuproptosis in liver IRI, and to elucidate the molecular mechanism by which adipose-derived stem cell exosomes (ADSC-Exos) exert therapeutic effects by regulating copper metabolism. Methods: Rat IRI models were established to evaluate copper metabolism dysregulation and cuproptosis activation. Subsequently, miniature pig models underwent laparoscopic IRI induction to assess ADSC-Exos's effects on copper homeostasis restoration over 7 days post-injury. Results: We found that liver IRI disrupts copper homeostasis through a dual pathway: it inhibits membrane transporters CTR1 and ATP7B to affect copper ion excretion, and down-regulates intracellular copper chaperones ATOX1, CCS and COX17 expression, resulting in intracellular copper metabolism disorders. Excessive copper ions will bind to the lipoylated protein DLAT, induce its oligomerization and mitochondrial Fe-S cluster protein depletion, eventually leading to cuproptosis in hepatocytes and aggravating IRI. The intervention of ADSC-Exos can effectively regulate the disorder of copper metabolism in hepatocytes, inhibit the occurrence of cuproptosis, and reduce liver IRI. Discussion: This study first confirmed the damage mechanism of cuproptosis pathway caused by liver IRI, and revealed the regulatory mechanism of ADSC-Exos to hinder the process of cuproptosis by repairing the copper metabolism pathway of hepatocytes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.